Spruce Street Capital LP Invests $15.87 Billion in Enanta Pharmaceuticals, Inc. $ENTA

Spruce Street Capital LP acquired a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the second quarter, Holdings Channel reports. The institutional investor acquired 1,088,731 shares of the biotechnology company’s stock, valued at approximately $15,873,698,000. Enanta Pharmaceuticals accounts for about 3.1% of Spruce Street Capital LP’s portfolio, making the stock its 11th biggest position.

Other institutional investors have also made changes to their positions in the company. Hillsdale Investment Management Inc. acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $6,660,000. Janus Henderson Group PLC increased its stake in Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after buying an additional 54,396 shares during the last quarter. Strs Ohio acquired a new stake in Enanta Pharmaceuticals in the 4th quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Enanta Pharmaceuticals by 333.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after buying an additional 2,758 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its position in Enanta Pharmaceuticals by 4.9% during the 1st quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock worth $444,000 after buying an additional 1,627 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Stock Up 4.7%

ENTA opened at $14.10 on Tuesday. Enanta Pharmaceuticals, Inc. has a 12-month low of $7.05 and a 12-month high of $17.15. The business has a 50 day moving average of $13.48 and a 200-day moving average of $13.46. The stock has a market cap of $410.59 million, a price-to-earnings ratio of -5.85 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The business had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. As a group, analysts expect that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.